Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate the efficiency, safety and short-term outcome of transurethral resection in saline plasma vaporization of the prostate (TURis-PVP), and to compare it to the standard TUR of the prostate (TURP). PATIENTS AND METHODS: In all, 155 patients with benign prostatic enlargement (BPE) secondary to benign prostatic hyperplasia (BPH), with a maximum urinary flow rate (Q(max) ) of <10 mL/s, an International Prostate Symptom Score (IPSS) of >19 and prostate volume of 30-80 mL were enrolled in this prospective, randomized trial. All patients were evaluated preoperatively and at 1, 3 and 6 months after surgery by IPSS, health-related quality of life (HRQL) score, Q(max) and postvoid residual urine volume (PVR). RESULTS: Patients from both series had similar preoperative characteristics. TURis-PVP and TURP were successfully performed in all cases (75 and 80, respectively). The operative duration, catheterization period and hospital stay were significantly shorter for TURis-PVP patients at 35.1 vs 50.4 min, 23.8 vs 71.2 and 47.6 vs 93.1 h, respectively (all P < 0.05). At the 1, 3 and 6 months follow-ups, improvements in the variables measured were better in the TURis-PVP group: the IPSS was 4.4 vs 8.3 and the Q(max) was 22.7 vs 20.5 mL/s at 1 month; the IPSS was 4.8 vs 8.6 and the Q(max) was 22.3 vs 20.0 mL/s at 3 months; and the IPSS was 5 vs 9.1 and the Q(max) was 21.8 vs 19.3 mL/s at 6 months (All P < 0.05). CONCLUSIONS: TURis-PVP represents a valuable endoscopic treatment alternative for patients with BPE, with superior efficacy, short-term results and complication rates compared with monopolar TURP.
No takes yet. Share an insight, caveat, or question.
Geavlete et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: